American biopharmaceutical company at Durham in North Carolina, founded in 1999 out of research on airway surface hydration at the University of North Carolina. Develops medicines that restore the fluid layer on airway and other epithelial surfaces, above all inhaled inhibitors of the epithelial sodium channel for cystic fibrosis and other muco-obstructive lung diseases, worked on these programmes in collaboration with Vertex Pharmaceuticals, and also studies dry eye and other epithelial conditions.
No comments available.
Leave your rating & comment